SCHEMBL6574456

SCHEMBL6574456

CCCS(=O)(=O)NC1CCCC1c1ccc(NCc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 10/20 0.47
FFAR1 O14842 2/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
GRIA2 P42262 1/20 0.40
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
HTT P42858 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6573066 0.86 GRIA4 (0.62) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6574449 0.83 GRIA4 (0.71) GRIA4FFAR1CA12CA1CA2
SCHEMBL6574452 0.83 GRIA4 (0.71) GRIA4FFAR1CA12CA1CA2
SCHEMBL6761964 0.82 GRIA4 (0.43) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6761010 0.80 GRIA4 (0.41) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573755 0.78 GRIA4 (0.48) GRIA4CA12CA1CA2CA9
SCHEMBL6573321 0.77 GRIA4 (0.42) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6575437 0.77 GRIA4 (0.42) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573336 0.76 GRIA4 (0.41) GRIA4GRIA2PSEN1PSEN2APH1B
SCHEMBL6573845 0.76 GRIA4 (0.41) GRIA4GRIA2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 GRIA4 9/4885FFAR1 147/4885CA12 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.